Ten Developments in the Use of Biologicals for Systemic Lupus Erythematosus

被引：1
|
作者：
Wallace, Daniel J. [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Los Angeles, CA 90095 USA
来源：
CURRENT RHEUMATOLOGY REPORTS | 2013年 / 15卷 / 07期
关键词：
Biologicals; Targeted therapy; Systemic lupus erythematosus; SLE; FDA; Treatment; Cutaneous lupus; Belimumab; Epratuzumab; T cell inhibition; B-LYMPHOCYTE STIMULATOR; DOUBLE-BLIND; DISEASE-ACTIVITY; PHASE-I; MONOCLONAL-ANTIBODY; CONTROLLED-TRIAL; SAFETY; BELIMUMAB; EFFICACY; RITUXIMAB;
D O I：
10.1007/s11926-013-0337-z
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Belimumab has recently been approved, and several other types of biological therapy with different mechanisms of action are currently in phase II and III studies. This review puts these approaches in context, emphasizing mechanistic categories and clinical trial designs. Most of the promising approaches involve B cell depletion or modulation. Post-approval experience with belimumab is critically reviewed.
引用
收藏
页数：8
相关论文
共 50 条
  • [41] New developments in the treatment of systemic lupus erythematosus
    Kjell Tullus
    Pediatric Nephrology, 2012, 27 : 727 - 732
  • [42] Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series
    Gualtierotti, Roberta
    Borghi, Maria Orietta
    Gerosa, Maria
    Schioppo, Tommaso
    Larghi, Paola
    Geginat, Jens
    Meroni, Pier Luigi
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : 643 - 647
  • [43] Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration
    Poh, Y. J.
    Baptista, B.
    D'Cruz, David P.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (10) : 925 - 938
  • [44] Advances in Drug Therapy for Systemic Lupus Erythematosus
    Zhao, Xinghua
    Zhang, Jiaojiao
    Liang, Yutong
    Li, Jie
    Ding, Shi
    Wang, Yang
    Chen, Ye
    Liu, Ju
    CURRENT MEDICINAL CHEMISTRY, 2021, 28 (06) : 1251 - 1268
  • [45] Subcutaneous belimumab in the treatment of systemic lupus erythematosus
    Elalouf, Ofir
    Keeling, Stephanie O.
    Touma, Zahi
    IMMUNOTHERAPY, 2018, 10 (13) : 1163 - 1173
  • [46] Belimumab in Systemic Lupus Erythematosus
    Srivastava, Ankita
    INDIAN JOURNAL OF DERMATOLOGY, 2016, 61 (05) : 550 - 553
  • [47] Treatment of systemic lupus erythematosus: Myths, certainties and doubts
    Ruiz-Irastorza, Guillermo
    Danza, Alvaro
    Khamashta, Munther
    MEDICINA CLINICA, 2013, 141 (12): : 533 - 542
  • [48] The dawn of a new era of therapies in systemic lupus erythematosus
    Mok, Chi Chiu
    RHEUMATOLOGY AND IMMUNOLOGY RESEARCH, 2020, 1 (01): : 31 - 37
  • [49] Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus
    Rao, Vijay
    Gordon, Caroline
    IMMUNOTHERAPY, 2014, 6 (11) : 1165 - 1175
  • [50] What's New in the Treatment of Systemic Lupus Erythematosus
    Liossis, Stamatis Nick
    Staveri, Chrysanthi
    FRONTIERS IN MEDICINE, 2021, 8
12345